Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes

NCT07695727 | Not Yet Recruiting

• 2 other identifiers: SG-2024-12380508 (GLUT1D)SG-2024-12380508
• Study Type: observational
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

Type 1 Diabetes is an autoimmune disease in which immune cells contribute to the destruction of insulin-producing pancreatic beta cells. This study investigates whether targeting glucose transporter 1 (GLUT1), a transporter involved in immune cell metabolism, may help modulate autoimmune responses associated with Type 1 Diabetes. The study uses previously collected and biobanked peripheral blood mononuclear cells (PBMCs) from individuals with Type 1 Diabetes. No additional visits, blood draws, or study-specific procedures will be performed on human participants.

Conditions

Type 1 Diabetes; Autoimmunity

Keywords

Autoimmunity; Type 1 Diabetes; GLUT1; Humanized mice; Immunometabolism; T cells

Outcome Measures

Primary Outcomes (1)

• Human Immune Cell Engraftment/Reconstitution

  Successful human immune cell engraftment/reconstitution will be assessed by detection and quantification of human CD45-positive cells and relevant immune cell subsets in peripheral blood and lymphoid tissues of recipient NOD scid gamma (NSG) mice.

  28 days after peripheral blood mononuclear cells (PBMCs) infusion

Secondary Outcomes (1)

• Quantitative and Phenotypic Profile of Human Immune Cell Subsets

  28, 44, and 58 days after PBMC infusion

Study Arms (1)

Adults With Type 1 Diabetes

Previously collected PBMC samples obtained from adult subjects with a documented diagnosis of Type 1 Diabetes and stored at the institutional Biobank of IRCCS Ospedale San Raffaele.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult individuals with a documented diagnosis of Type 1 Diabetes whose peripheral blood mononuclear cell (PBMC) samples were previously collected and stored at the institutional Biobank/Biological Resources Center of IRCCS Ospedale San Raffaele. The study population consists of subjects who previously provided informed consent for the collection, storage, and research use of biological material and associated coded data. No prospective enrollment, additional sampling, or other study-specific procedures involving human participants are planned.

You may qualify if:

• PBMC samples obtained from adult subjects aged 18 years or older at the time of sample collection.
• Documented diagnosis of Type 1 Diabetes.
• PBMC samples already collected and stored in the institutional Biobank of IRCCS Ospedale San Raffaele.
• PBMC samples obtained from subjects who had previously provided written informed consent for the collection, storage, and research use of biological material and associated data.

You may not qualify if:

• PBMC samples obtained from subjects younger than 18 years at the time of sample collection.
• Presence of relevant concomitant diseases or clinical conditions that, in the Investigator's judgment and based on available records, may interfere with the interpretation of immunological analyses or with the study objectives.
• Insufficient sample availability, inadequate sample quality, or missing essential sample-related information preventing use of the PBMC sample for the planned research activities.

Sponsors & Collaborators

• IRCCS San Raffaele: lead

Study Sites (1)

IRCCS San Raffaele Scientific Institute

Milan, 20132, Italy

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1; Autoimmune Diseases

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Immune System Diseases

Study Officials

• Carla Di Dedda, PhD

  IRCCS San Raffaele

  PRINCIPAL INVESTIGATOR

• Lorenzo Piemonti, MD

  IRCCS San Raffaele

  STUDY CHAIR

Central Study Contacts

Carla Di Dedda, PhD

CONTACT

+39 0226434369; didedda.carla@hsr.it

Lorenzo Piemonti, MD

CONTACT

+39 0226432706; piemonti.lorenzo@hsr.it

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Researcher, Division of Immunology, Transplantation and Infectious Diseases

Study Record Dates

• First Submitted: July 6, 2026
• First Posted: July 10, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2029
• Study Completion (Estimated): September 1, 2029
• Last Updated: July 14, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)